Cannara Biotech Inc. (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0) has announced an expansion of its long-term international supply agreement with Curaleaf International Limited, originally announced on July 14, 2026. The amended agreement carries a potential aggregate contract value of approximately C$34 million over its two-year term, up from up to C$21 million under the original arrangement. The expansion signals growing demand for Québec-grown cannabis in international medical markets and investors may be watching for progress on EU-GMP certification as a key commercial milestone.

Key Points

  • Cannara Biotech Inc. (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0) is a vertically integrated Québec-based cannabis producer
  • The amended international supply agreement with Curaleaf International has a potential aggregate value of approximately C$34 million over two years
  • 15 of 24 grow rooms are currently active at Cannara's Valleyfield facility, with a fully funded build-out plan in place
  • Investors should watch for developments on EU-GMP certification for Cannara's Valleyfield processing centre

Amended Agreement Raises Potential Contract Value to C$34 Million

The expanded agreement with Curaleaf International builds on Cannara's first long-term international supply commitment. Based on committed supply volumes and the terms and conditions of the agreement, the potential aggregate contract value has increased to approximately C$34 million over the two-year term, compared with up to C$21 million under the original arrangement. The release states the expanded relationship is intended to grow international sales through Curaleaf's established distribution network in Europe, Canada, and Australasia, while supporting Cannara's continued Canadian growth strategy.

Valleyfield Facility Capacity Underpins Supply Commitments

The company disclosed that 15 of its 24 grow rooms at its Valleyfield facility are currently active, with remaining capacity available to scale production as demand increases. Chief Operating Officer Niko Sosiak stated in the release that a fully funded build-out plan is in place, providing what the company describes as a clear runway to grow output while maintaining quality and cost discipline. Cannara's two Québec mega facilities span over 1,600,000 sq. ft., providing potential annualized cultivation output of 100,000 kg, according to the announcement.

EU-GMP Certification Pursuit Continues with Curaleaf Support

Curaleaf is continuing to support Cannara in its pursuit of EU-GMP certification for the processing centre at its Valleyfield facility. In the interim, cannabis flower supplied under the agreement will be dried and processed under EU-GMP conditions at Curaleaf's EU-GMP certified facility in Canada before being released into international medical markets. The disclosure suggests this interim arrangement enables Cannara to access international markets while its own certification process advances, though the timeline for certification was not confirmed in the announcement.